Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

July 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

COPD

Interventions

DRUG

Inhaled PT005

inhaled, twice daily for 1 week duration

DRUG

Inhaled Placebo

inhaled, twice daily for 1 week duration

DRUG

Formoterol Fumarate 12 µg (Foradil Aerolizer)

inhaled, twice daily for 1 week duration

Trial Locations (1)

Spartanburg Medical Research, Spartanburg